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Objective: We investigated the effects of single or repetitive intra-articular injections of synovial
mesenchymal stem cells (MSCs) on a rat osteoarthritis (OA) model, and elucidated the behaviors and
underlying mechanisms of the stem cells after the injection.
Design: One week after the transection of the anterior cruciate ligament (ACL) of wild type Lewis rats,
one million synovial MSCs were injected into the knee joint every week. Cartilage degeneration was
evaluated with safranin-o staining after the ﬁrst injection. To analyze cell kinetics or MSC properties,
luciferase, LacZ, and GFP expressing synovial MSCs were used. To conﬁrm the role of MSCs, species-
speciﬁc microarray and PCR analyses were performed using human synovial MSCs.
Results: Histological analysis for femoral and tibial cartilage showed that a single injection was inef-
fective but weekly injections had signiﬁcant chondroprotective effects for 12 weeks. Histological and
ﬂow-cytometric analyses of LacZ and GFP expressing synovial MSCs revealed that injected MSCs
migrated mainly into the synovium and most of them retained their undifferentiated MSC properties
though the migrated cells rapidly decreased. In vivo imaging analysis revealed that MSCs maintained in
knees while weekly injection. Species-speciﬁc microarray and PCR analyses showed that the human
mRNAs on day 1 for 21 genes increased over 50-fold, and increased the expressions of PRG-4, BMP-2, and
BMP-6 genes encoding chondroprotective proteins, and TSG-6 encoding an anti-inﬂammatory one.
Conclusion: Not single but periodic injections of synovial MSCs maintained viable cells without losing
their MSC properties in knees and inhibited osteoarthritis (OA) progression by secretion of trophic
factors.
© 2016 The Authors. Published by Elsevier Ltd on behalf of Osteoarthritis Research Society International.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).Introduction
Osteoarthritis (OA) is the most prevalent degenerative joint
disease, associated with multiple risk factors such as age, sex, mal-I. Sekiya, Center for Stem Cell
l University, 1-5-45 Yushima,
017; fax: 81-3-5803-0192.
r Ltd on behalf of Osteoarthritis Re
d/4.0/).alignment, obesity, genetic factors, and trauma1. Although the
incidence of OA is rising due to aging populations2, no effective
disease-modifying drug has been developed due to the disease's
complicated chronic pathology, affecting not only cartilage but also
subchondral bone and synovium3.
Mesenchymal stem cells (MSCs), ﬁrst described in human bone
marrow4, are emerging as promising cell-based therapeutics for a
wide range of diseases5. MSCs are also isolated from synovium6,
and synovial MSCs are particularly suited for cartilage repair as theysearch Society International. This is an open access article under the CC BY-NC-ND
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previously reported on synovial MSCs for cartilage regeneration in
an osteochondral defect model in rabbits9 and pigs10. We also ob-
tained satisfactory results by administration of synovial MSCs to
cartilage defects in humans11.
Recently, several studies have shown the effectiveness of a
single intra-articular injection of stem cells for OA in animals12e15
and humans16e18. The deﬁnitive mechanisms behind stem cell-
based injection therapies are still unclear, but putative mecha-
nisms have been proposed such as anti-inﬂammatory effects13,
regeneration of the meniscus12, or direct differentiation into func-
tional chondrocytes14. The number of injected stem cells has been
shown to decrease immediately following a single dose injec-
tion13,19, which indicate that a single treatment is not enough to
overcome the long-term pathology of chronic OA. In this study, we
compared the chondroprotective effects of periodic injections of
synovial MSCs with that of a single injection, and analyzed cell
kinetics and behavior with rat luciferase, LacZ, and GFP expressing
synovial MSCs in a rat OAmodel. We also determinedMSCs' trophic
factor contributions by species-speciﬁc microarray and PCR ana-
lyses using human synovial MSCs in a rat OA model.Materials and methods
Animals
A total of 76 wild type male Lewis rats (Charles River Labora-
tories Japan, Kanagawa, Japan) at 10e12 weeks old were used for
the experiments. All animal care and experiments were conducted
in accordance with the institutional guidelines of the Animal
Committee of Tokyo Medical and Dental University. Luciferase
expressing transgenic rats (N¼ 4)20, LacZ expressing transgenic rats
(N ¼ 4) and green ﬂuorescence protein expressing transgenic rats
(N ¼ 4)21 (all provided by Jichi Medical University, Tochigi, Japan)
were also used for analyses of in vivo imaging, detection of X-Gal
staining, and ﬂow cytometry. Rats were anesthetized by isoﬂurane
inhalation and intraperitoneal injection of tribromoethanol.Preparation of synovial MSCs
This study was approved by an institutional review board, and
informed consent was obtained from all human subjects. To pre-
pare human synovial MSCs, synovium was harvested from donors
during anterior cruciate ligament (ACL) reconstruction surgery for
ligament injury. Synovial MSCs from rats or humans were prepared
as previously described8,22e24. In summary, harvested synovium
was minced and digested with collagenase for three hours, and
cells were disseminated into complete culture medium and incu-
bated at 37C with 5% humidiﬁed CO2. After 14 days, cells were
collected and preserved at 80C. For an injection, 1  106 synovial
MSCs were prepared in 50 ml of phosphate buffered saline (PBS).
Synovial MSCs from luciferase, LacZ, and GFP expressing rats were
also prepared in the same manner (Lucþ MSCs, LacZþ MSCs and
GFPþ MSCs).Surgery and injection of synovial MSCs
After the patellar tendon was dislocated laterally, ACL was
transected completely. The rats were allowed to walk freely in their
cages. From 1week following the surgery, the rats had intra-
articular injection of PBS alone (control group) every week,
1  106 synovial MSCs at one time (single group), or every week
(weekly group).Evaluations of cartilage degeneration
Both the femoral condyle and the tibial plateau were evaluated
by India Ink staining for macroscopic observation. For the histo-
logical examination, both femoral and tibial cartilage were ﬁxed in
4% paraformaldehyde for 7 days, and decalciﬁed in 20% ethylene
diamine tetra acetic acid (EDTA) solution for 21 days, then
embedded in parafﬁn wax. The specimens were sectioned in the
sagittal plane at 5 mm and stained with safranin-o and fast green.
Cartilage degeneration was evaluated using the Osteoarthritis
Research Society International (OARSI) scoring system in the
medial part of the femur and tibia25.
In vivo bioluminescent imaging
A noninvasive bioimaging system IVIS (Xenogen, Alameda, CA)
was used after single or weekly injections of 1  106 Lucþ MSCs.
Under anesthesia with isoﬂurane, d-luciferin was administrated
(20 mg/ml, 50 ml) at 1, 7, 14, 21, and 28 days after the ﬁrst injection of
Lucþ MSCs, and photons were detected by IVIS (N ¼ 3, each). As a
normal control, intact knees were also evaluated. The signal in-
tensity was quantiﬁed as photon ﬂux in units of photons per sec-
onds in the region of interest.
Detection of LacZ expression
X-Gal staining was performed after injection of 1  106 LacZþ
MSCs. The rats were sacriﬁced at 1 day after injection, and the knee
specimens were ﬁxed with a ﬁxative solution (0.2% glutaraldehyde,
2 mM MgCl2, and 5 mM EDTA) in PBS for 30 min at room tem-
perature and rinsed 3 times in PBS towash out the ﬁxative solution.
They were treated with an X-gal staining solution (1 mg/ml 5-
bromo-4-chloro-3-indolyl-b-D-galactopyranoside, 2 mM MgCl2,
6 mM potassium ferricyanide, and 6 mM potassium ferrocyanide)
under incubation at 37C for 3 h. After taking pictures of macro-
scopic ﬁndings, they were subsequently ﬁxed again in 4% para-
formaldehyde. The specimens were decalciﬁed with 0.5 M EDTA
(pH 7.5) for 21 days, and embedded in parafﬁnwax, then sectioned
and counterstained with eosin.
Flow cytometry
1  106 GFPþ MSCs were injected 1week after the ACLT, then
synovium was harvested 1day after the injection, following diges-
tion with collagenase V for three hours. After ﬁltering through a
70 mm cell strainer and centrifuging at 1500 rpm for 5 min, cells
were suspended in ice-cold Hank's balances salt solution and then
stained for 30 min on ice with a monoclonal antibody of APC-
conjugated CD90 (Becton, Dickinson and Company, Franklin
Lakes, NJ, USA). Synovial ﬂuid was also extracted from the same
knee, and prepared in the same manner without collagenase
digestion. Propidium iodide (PI) ﬂuorescence was measured, and a
live cell gate was deﬁned that excluded the cells positive for PI.
Additional gates were deﬁned as positive for GFP and CD90. Double
positive cells were further analyzed for PE-conjugated CD29, PE-
conjugated CD31, and PEcy7-conjugated CD45 (Biolegend, San
Diego, CA, USA). Flow-cytometric analysis and sorting were per-
formed on a MoFlo (Beckman Coulter, Brea, CA, USA), and the data
were analyzed using FlowJo software (Tree Star, Ashland, OR,
USA)26.
Oligonucleotide microarray
RNA was isolated from synovium 1, 3, and 7 days after injection
of 1 106 hMSCs (n¼ 4, each) using TRIzol solution (Invitrogen Life
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(Roche Applied Sciences, Indianapolis, IN, USA). A microarray
analysis was performed using 500 ng of total RNA from each sample
and GeneChip® Rat Genome 230 2.0 probe arrays (Affymetrix,
Santa Clara, CA, USA) and/or GeneChip® Human U-133 plus 2.0
probe arrays. Data was analyzed with GeneSpring GX software
version 12.5 (Agilent Technologies, Palo Alto, CA, USA). To
normalize the variations in staining intensity among chips, the
signal values for all genes on a given chip were divided by the
median value for the expression of all genes on the chip. To elim-
inate genes containing only background signals, genes were
selected only if the raw values of the signal were more than the
lower limit of the conﬁdence interval, and expression of the gene
was judged to be ‘present’ using MAS5 algorithm in Expression
Console Version1.1 (Affymetrix). The microarray data were depos-
ited in the Gene Expression Omnibus (GEO accession no.
GSE61617).
Quantitative real-time reverse transcriptase polymerase chain
reaction (RT-PCR)
First-strand cDNAs were synthesized using a Transcriptor First-
strand cDNA synthesis kit (Roche), and Q-PCR analyses were per-
formed using a LightCycler 480 Probe Master system (Roche) with
human-speciﬁc b-actin primers and a probe. For the assay of hu-
man and rat mRNA, PCR primers of human and rat RNA are listed in
Supplementary Tables 2 and 3. Relative mRNA expression levels
were calculated as described by Niikura et al.27.
Statistical analysis
Statistical analysis was performed with the StatView 5.0 pro-
gram (SAS Institute, Cary, NC). Comparisons between the two
groups for PCR analysis were analyzed using the ManneWhitney's
U-test. Comparisons between multiple groups were analyzed using
the KruskaleWallis test. P values less than 0.05 were considered to
be statistically signiﬁcant. Error bars indicated 95% CI.
Results
Weekly intra-articular injections of synovial MSCs inhibit OA
progression
To determine the chondroprotective effects of synovial MSCs in
detail, we administered weekly intra-articular injections of syno-
vial MSCs in a rat ACLT model to compare these effects against
those of a single injection [Fig. 1(A)]. In the control group (PBS in-
jection) or single injection group, signiﬁcant cartilage lesions
appeared at 8 weeks macroscopically [Fig. 1(B) and (C); white ar-
rows] and histologically [Fig. 1(D) and (F)]. These cartilage pathol-
ogies progressively worsened at 12 weeks. On the other hand,
weekly injections of synovial MSCs better preserved cartilage both
macroscopically and histologically, when stained with safranin-o.
The OARSI score in the weekly injection group was signiﬁcantly
better in the medial tibial plateau at 8 and 12 weeks [Fig. 1(E)] and
in the medial femoral condyle at 12 weeks [Fig. 1(G)]. Cartilage
immunostaining for type II collagen was also better preserved in
the weekly injection group (Supplementary Figs. 1 and 2). To assess
synovial inﬂammation, synovium including the infrapatellar fat
pad of the whole knee joint was evaluated. In the control group and
the single injection group at 8 and 12 weeks, hyperplasia of the
synovial lining layers and/or increased cell inﬁltration were/was
observed [Supplementary Fig. 3(A); black arrows]. Synovitis score
at 12 weeks was lower in the weekly injection group than in thecontrol and single injection groups in all three rats we examined in
each group [Supplementary Fig. 3(B)].
Weekly injections of synovial MSCs maintain viable cells in knees
To examine cell viability in vivo, we evaluated photons from
Lucþ MSCs using an IVIS system. In vitro imaging of luciferase ac-
tivity showed that the system enabled detection of as few as one
thousand MSCs over the background in the linear dose-dependent
output of luminescence [Fig. 2(A)]. For in vivo imaging analyses in
the weekly group, we injected Lucþ MSCs just after the evaluation
of IVIS, except the initial injection [Fig. 2(B)]. We evaluated three
rats per group at 5 time points. Although synovial MSCs rapidly
decreased at 1 week and almost disappeared at 2e3 weeks after a
single injection in the ACLT knee, MSCs could be detected at every
evaluation time point in the case of weekly injections in all cases
[Fig. 2(C) and (D)].
To examine the migration of MSCs in the knee joint, we then
evaluated X-Gal staining after the injection of LacZþ MSCs
[Fig. 3(A)]. One day post injection, dark blue areas of LacZþ MSCs
were present in the synovium both macroscopically and histolog-
ically [Fig. 3(B); red arrow, and C; black arrows]; however, no
migration of LacZþ MSCs into the cartilage or meniscus was
observed. To determine if the injected MSCs were able to survive in
the synovial ﬂuid, we cultured synovial ﬂuid 1 day after the in-
jection of LacZþ MSCs into the ACLT knee, and colonies were eval-
uated by staining for X-Gal and crystal violet [Supplementary
Fig. 3(A)]. We analyzed synovial ﬂuid from three knees, and col-
onies were barely detectable from the intact knee. On the other
hand, a constant number of colonies were detected after ACLT
knees irrespective of MSC injection [Supplementary Fig. 4(A) and
(B)]. Approximately 10% of colonies were stained with X-Gal
[Fig. 4(A)], which indicated a small number of injected synovial
MSCs survived in the synovial ﬂuid.
Injected synovial MSCs retain their MSCs properties after migration
into the synovium
We next determined if the injected cells would retain their
undifferentiated features by use of GFPþ MSCs [Fig. 4(A)]. Using
ﬂow cytometry, we sorted GFPþ MSCs engrafted within the syno-
vium [Fig. 4(B)] and synovial ﬂuid from four knees. Before the in-
jection, most GFPþMSCs expressed CD29 and CD90, and lacked the
expression of CD31 and CD45 [Fig. 4(C)]. After migrationwithin the
synovium, the surface markers of the GFPþ cells did not change
[Fig. 4(D) and Supplementary Fig. 5]. The ratio of GFPþ cells against
total live cells gradually decreased with time [Fig. 4(E) and (F)], but
the ratio of CD90 positive cells within the GFPþ cells was main-
tained at approximately 90% even at 28 days after injection
[Fig. 4(G)]. From the synovial ﬂuid, the ratio of GFPþ cells against
total live cells was also low [Fig. 4(E) and (F)] and their CD90 pos-
itive ratio was approximately 90% [Fig. 4(G)]. The sorted GFPþ cells
differentiated into chondrocytes, adipocytes, and were calciﬁed
in vitro (Supplementary Fig. 6).
Injected synovial MSCs increase expressions of genes related to
chondroprotection and anti-inﬂammation after migration into the
synovium
To quantify the number of synovial MSCs engrafted within the
synovium, we applied a xenotransplantation model19,28 and pre-
pared standard curves of b-actin from synovium mixed with pre-
determined numbers of hMSCs just before homogenization
[Fig. 5(A)]. We also puriﬁed RNA from the synovium injected with
hMSCs, and assayed it with a quantitative RT-PCR assay speciﬁc for
Fig. 1. Weekly intra-articular injections of synovial MSCs inhibited OA progression and attenuated synovitis in a rat OA model. (A) Schema of the study. (B) Representative
macroscopic features of the tibial plateau from three specimens. Cartilage erosion is indicated by white arrows. Scale bar, 1 mm. A, anterior; P, posterior; M, medial; L, lateral. (C)
Representative histological sections stained with safranin-o for the tibial plateau. Left panel, low magniﬁcation. Scale bar, 1 mm. OARSI score for each section is indicated. Right
panel, high magniﬁcation. Scale bar, 100 mm. (D) OARSI score for histology of the tibial plateau (N ¼ 6, P < 0.05). Error bars represent 95% conﬁdence intervals. (E) Representative
features of infrapatellar fat pad stained with hematoxylin & eosin. Proliferation of lining layer or inﬁltrations of cells are indicated with black arrows. Left panel, low magniﬁcation.
Scale bar, 500 mm. Right panel, high magniﬁcation. Scale bar, 100 mm. (F) Synovitis score for histology. Each score is plotted (N ¼ 3). (G) OARSI score for histology of the femoral
condyle (N ¼ 6, P < 0.05). Error bars represent 95% conﬁdence intervals.
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hMSCs were recovered in the rat synovium at 1 day, and 103 hMSCs
were recovered at 3 days [Fig. 5(B) and (C)]. No human MSCs were
detected at 7 days.
The use of a xenotransplantation made it possible to follow
changes in both the injected hMSCs and the endogenous rat cells in
the synovium simultaneously. We evaluated the human and rat
transcriptomes in the synovium injected with 106 hMSCs 1 day
after injection. Rat synovium mixed with 104 hMSCs was used as a
control. Fold changes of human b-actin and other housekeeping
genes, such as hGAPDH, hNPAT, and hCTNNB1, were between 0.5 and
2.0, suggesting that the normalization is applicable (SupplementaryTable 4). After ﬁltering for cross-hybridization with human mRNA,
the data showed that after migration within the synovium, the
human mRNAs on day 1 for 5 genes increased over 100-fold, 21
genes increased over 50-fold, and about 255 genes increased over
10-fold, and about 1060 genes increased over 2-fold. The 20 most
highly up-regulated human transcripts included hPRG-4 and hBMP-
2 (Table I). We then conﬁrmed these signiﬁcant increases by RT-PCR
for hPRG-4, hBMP-2, and hBMP-6, which are related to cartilage
homeostasis, and hTSG-6, a known anti-inﬂammatory cytokine
[Fig. 5(D)]. These results strongly suggest that various growth fac-
tors were secreted by hMSCs after migration into the synovium.
With regard to transcripts related to chondrogenesis, hCol2a1
Fig. 2. Weekly injections of synovial MSCs maintained viable cells in knees. (A) In vitro bioluminescent imaging of varying numbers of luciferase positive synovial MSCs. (B) Schema
for the in vivo imaging analysis. In the weekly group, the injection was performed immediately after the analysis at 1, 2, and 3 weeks. (C) In vivo imaging analyses after injection of
Lucþ MSCs into the knee joint (N ¼ 3, each). (D) Sequential quantiﬁcation of luminescence intensity. Each intensity is plotted and the average is shown as a line graph (N ¼ 3).
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which suggested that hMSCs showed no signs of chondrogenesis in
the synovium (Supplementary Table 5). Microarray data also indi-
cated that injection of human MSCs up-regulated the expression of
406 rat transcripts 2-fold or more (Supplementary Table 6). We
focused on the pro-inﬂammatory cytokines or cytokines related to
proliferation such as rIL-1b and rVEGF, but no signiﬁcant difference
was observed by real-time RT-PCR [Fig. 5(D)].
Discussion
Not single but weekly intra-articular injections of synovial MSCs
inhibited OA progression and attenuated synovitis in a rat OA
model. After the administration of MSCs into the knee joint, it is
well known that the number of cells rapidly decreases13,19, and we
obtained similar results from our experiments. These suggest that
periodic injections are necessary to maintain both the number and
the efﬁcacy of MSCs for the long term to improve the condition of
OA. In fact, a single injection of synovial MSCs had a minimal effect
in the current study, which demonstrates the importance ofperiodic administration of stem cells against OA. This is the ﬁrst
study demonstrating the effectiveness of periodic MSC dosing for
chronic pathology in the knee joint.
There have been reports describing the effect of a single injec-
tion of MSCs in different OA models12e15. Ter Huurne et al. injected
adipose-derived stem cells into the knee in a mouse OA model
induced by intra-articular injection of collagenase13. OA progres-
sion was inhibited when evaluated 42 days after a single injection
of stem cells due to the attenuation of synovitis. However, although
GFP-transfected cells were detectable in the synovium 24 h after
injection, they were no longer detectable at day 5 and thereafter.
Murphy et al. induced OA in goats by removal of the medial
meniscus and resection of the ACL, followed by intra-articular in-
jection of bone marrow MSCs. Meniscus regeneration was stimu-
lated though the ACL was not repaired, and progression of the
articular cartilage degeneration was reduced at 20 weeks12. In this
model, GFP-transfected MSCs were still detected in the center of
neomeniscal tissue 6weeks after injection. They concluded that the
chondroprotective effects of stem cells were due to the regenera-
tion of the meniscus. These reports of short vs long-term stem cell
Fig. 3. Injected synovial MSCs migrated into the synovium or suspended in synovial ﬂuid. (A) Schema for the study using LacZþ MSCs. (B) Macroscopic features of LacZþ MSCs
migrated into the synovium after X-Gal staining. (N ¼ 3, Scale bar, 1 mm, S; synovium, F; femoral condyle, T; tibial cartilage, M; meniscus) (C) Histological sections counterstained
with eosin (Scale bars, 500 mm/low magniﬁcation, 20 mm/high magniﬁcation). LacZþ MSCs are indicated by black arrows. The boxed areas in insets are shown at a higher-
magniﬁcation in the larger panels. (D) X-Gal staining and colony forming assay for synovial ﬂuid of normal knee, ACLT knee, and ACLT knee injected with LacZþ MSCs 1 day
before (N ¼ 3, each). In “ACLT knee injected with LacZþ MSCs,” the same dish was shown before and after crystal violet staining. Scale bar, 100 mm. (E) Quantiﬁcation of colony
number. Each value is plotted and the average is shown as a crossbar (N ¼ 3).
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protection is observed in each. Here, we found that stem cells
remained primarily in the synovium after repeated injections,
though they disappeared 7 days after a single injection. We
therefore, administered subsequent dosings accordingly, every 7
days. It is unclear if these multiple injections would improve the
therapeutic effects seen in some single injection models where
long-term cell survival is observed.
From our analyses using LacZþ or GFPþ MSCs, injected MSCs
primarily migrated into the synovium, but they were not detected
in the cartilage. This is a distinct result from previous studies in
which stem cells survived within the osteochondral defect exposed
to bone marrow29,30. We transplanted synovial MSCs 1 week after
ACLT, and at that time cartilage degeneration was not obvious. In
cases where MSCs were administrated later, when the articular
cartilage was more degenerated, MSCs may be detected in the
cartilage.
Other efforts have been directed at investigating an endogenous
synovial MSC niche, and Kurth et al. suggested that stem cells in the
synovium were distinct from pericytes from the results of double
nucleoside labeling analysis and immunohistochemistry31. We
previously identiﬁed that the numbers of a-smooth muscle actin-
positive vessels and CD31þ endothelial cells were different
among the harvest sites of the synovium in human OA, and these
numbers were strongly correlated with the number of colony-
forming synovial MSCs32. We speculated that the niche of these
cells would be near vascular regions. However, the behavior of
MSCs after transplantation remain uncertain33.When administered
MSCs differentiate into the injured tissue, they lose their MSC
properties. To determine this, we injected GFPþ MSCs into the wildtype rat knee and sorted only GFPþ cells by ﬂow cytometry that
migrated into the synovium. We surprisingly identiﬁed that almost
all GFPþ cells retained their MSCs properties, positive for CD90 and
CD29, negative for CD31, CD45. In addition, their properties
remained even at 4 weeks after the injection, although the number
of GFPþ cells decreased. From these ﬁndings, we conﬁrmed that
synovial MSCs maintained viability with stemness after engraft-
ment in the synovium, without being directed to differentiation.
This is the ﬁrst study elucidating that MSCs retained stemness after
intra-articular injection.
Underlying mechanisms of stem cell therapy include two major
roles: the replacement of injured tissues34, and the production of
trophic factors35. To clarify the effect of synovial MSCs after
migration, we analyzed rat synovium with its migrated hMSCs by
species-speciﬁc microarrays and PCR analyses. hMSCs gene
expression changed after hMSCs migrated within the rat synovium.
We found signiﬁcant up-regulation of several cytokines, such as
PRG-4, BMPs, and TSG-6, which are key trophic factors for chon-
droprotection. PRG-4, known as lubricin, normally produced by
synoviocytes or superﬁcial zone chondrocytes, plays an important
role in homeostasis and maintenance of cartilage36,37. Intra-
articular injection of lubricin prevented cartilage degeneration in
a rat ACLT model38. BMP-2 and -6 are critical for the differentiation
of chondrocytes, cartilage matrix synthesis39, and cartilage pro-
tection40. TSG-6 has been previously reported to be secreted by
engrafted MSCs to suppress inﬂammation in myocardial infarction,
peritonitis, and inﬂammatory cornea injury models28,41,42. Two
major pathologies of OA include degeneration of articular cartilage
and synovitis1; therefore, PRG-4 and BMPs chondroprotectively
affected the articular cartilage, and TSG-6 delayed secondary
Fig. 4. Injected synovial MSCs retained their MSC properties after migration into the synovium. (A) Schema for the ﬂow-cytometric assay. PI (B) Macroscopic features of the GFPþ
MSC injected knee. The boxed area is shown at a higher-magniﬁcation. Scale bar, 80 mm (C) Flow-cytometric proﬁles of GFPþ MSCs before injection. (D) Flow-cytometric proﬁles of
GFPþ MSCs 1 day after migration within the synovium. (E) Representative ﬂow-cytometric proﬁles of cells derived from the synovium and in the synovial ﬂuid for GFPþ and CD90
positive cells. In the negative control, synovial cells without any GFPþ MSCs were analyzed without CD90 antibody (N ¼ 4, each). (F) Sequential ratio of GFPþ MSCs per total alive
cells in the synovium. Each value is plotted and the average is shown as a crossbar (N ¼ 4). (G) Ratio of CD90 positive cells in the GFPþ cells (N ¼ 4).
N. Ozeki et al. / Osteoarthritis and Cartilage 24 (2016) 1061e1070 1067cartilage degeneration through attenuating synovitis. We consid-
ered that these multiple trophic effects have a considerable
advantage in the use of stem cells, and these advantages are not
accomplished by the administration of one single drug.
The analyses for synovial MSC viability and gene expression
were performed in a xenotransplantation model. Previous reports
clariﬁed the function of MSCs using human cells into mice28 or
rats43. The migrated MSCs may endure a different response from
the joint environment and elicit a different response to the joint in
the case of an allogeneic transplantation model. Therefore, more
attention should be given to the possible differences between
allogeneic or autologous transplantation model.
We did not identify the trophic effect of theMSCs that survived in
the synovialﬂuid aswasdone in the synoviumbecause the amountof
synovialﬂuidwasextremely low, and thenumberof surviving cells in
the synovial ﬂuid was small. Previously, we reported that higher
numbers of colonies were obtained from synovial MSCs of ACL
injured knee, meniscus injured knee, or OA knees than healthy con-
trol knees44e46. These results indicated that stem cells are recruited
to the synovial ﬂuid as a response to injury of the joint, and theymay
have somebiological effect. It is the next step to analyzewhat induces
the recruitment of stem cells into the joint environment.In this model, we used young rats with open growth plates;
however, the population of OA patients is usually older adults. In
human studies, we reported that the proliferation and differentia-
tion potentials of synovial MSCs in elderly OA patients were com-
parable to those in young patients with ACL injury47. But, though
the quality of isolated synovial MSCs from donors of various ages
may be similar; we also have to consider that the joint environment
inwhichwe apply synovial MSCs is critically affected by age, degree
of OA, and condition of inﬂammation.
To achieve repeated injections, the preparation of a considerable
number of stem cells is necessary. Autologous synovial MSCs are
preferable to allogeneic MSCs to avoid immune reactions in clinical
situations. From our experience, a sufﬁcient number of MSCs can be
prepared from the synovium in most donors7,11 and yields, prolif-
eration and chondrogenic potential of synovial MSCs were similar
in young donors and elderly donors47. Therefore, it is possible to
obtain a high number of synovial MSCs for the repeated injections
in OA patients. However, the optimal number of stem cells required
for an intra-articular injection is still controversial. Jo et al. per-
formed 3 dose-escalation cohorts in OA patients; a low-dose
(1  107 cells), mid-dose (5  107) and high-dose (1  108)
group. Second-look arthroscopy and histology showed that the
Fig. 5. Injected synovial MSCs increased expression of genes related to chondroprotection and anti-inﬂammation after migration into the synovium. (A) Schema for the xeno-
transplantation assay. (B) Standard curve showing relationship between the number of hMSCs mixed with rat synovium and DCt (difference between expression levels of human
and rat b-actin). DCt from the rat synovium after injection of hMSCs was also plotted. (C) The number of viable hMSCs in rat synovium after injection. Each value was obtained from
the standard curve shown in Fig. 5(B). The value at 7 days was below the detection limit. (D) Human speciﬁc and rat speciﬁc gene expressions in the synovium of rat at 1 day by RT-
PCR. Control group had 104 hMSCs mixed with synovium. (E) Possible mechanism delaying the progression of cartilage degeneration by weekly injections of synovial MSCs in a rat
OA model. Injected synovial MSCs migrate into the synovium and express BMPs, PRG-4, TIMP-1, etc. that prevent cartilage degradation, and also TSG-6 that inhibits inﬂammation.
Table I
The top 20 human transcripts up-regulated in the hMSCs that migrated within the synovium
Probe set ID Gene symbol Gene title FC
209278_s_at TFPI2 Tissue factor pathway inhibitor 2 252.6
206007_at PRG4 Proteoglycan 4 162.3
206300_s_at PTHLH Parathyroid hormone-like hormone 130.5
1558048_x_at T.L Transcribed locus 107.5
219043_s_at LOC285359///PDCL3 Phosducin-like 3 pseudogene///phosducin-like 3 102.6
210145_at PLA2G4A Phospholipase A2, group IVA (cytosolic, calcium-dependent) 92.5
205289_at BMP2 Bone morphogenetic protein 2 87.4
201909_at RPS4Y1 Ribosomal protein S4, Y-linked 1 75.5
210108_at CACNA1D Calcium channel, voltage-dependent, L type, alpha 1D subunit 63.6
203477_at COL15A1 Collagen, type XV, alpha 1 63.3
208051_s_at PAIP1 Poly(A) binding protein interacting protein 1 62.8
205932_s_at MSX1 msh homeobox 1 61.6
203840_at BLZF1 Basic leucine zipper nuclear factor 1 61.6
237496_at T.L Transcribed locus 61.0
229174_at C3orf38 Chromosome 3 open reading frame 38 59.4
202196_s_at DKK3 dickkopf homolog 3 (Xenopus laevis) 57.2
229088_at ENPP1 Ectonucleotide pyrophosphatase/phosphodiesterase 1 56.5
232458_at COL3A1 Collagen, type III, alpha 1 56.0
217790_s_at SSR3 Signal sequence receptor, gamma (translocon-associated protein gamma) 55.5
219163_at ZNF562 zinc ﬁnger protein 562 53.2
RNAwas recovered 1 day after the intra-articular injection of humanMSCs for analysis on human speciﬁc microarrays (Affymetrix). Signal intensities were compared between
samples from synovium 1 day after injection of the ACLT knees and control samples from 104 hMSCs added to the synovium of ACLT knees. Values are fold increase over values
for control. T.L; Transcribed locus. Almost all the ﬂags in these control samples were ‘Absent’.
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improvement in function with reduced pain17. However, Kim et al.
prepared an average of 4.3  106 stem cells for OA patients48, and
saw signiﬁcant improvement of both IKDC and Tegner activity
scores. Ongoing studies in the ﬁeld, like these, will help identify the
optimal number of synovial MSCs and frequency of injections for
clinical use in OA patients.
Finally, we summarized the chondroprotective mechanism of
MSC injection in the current model. Without any treatment after
the ACLT, cartilage degeneration appears at the cartilage surface
and gradually progresses into the deep zone, demonstrating
chronic OA. When synovial MSCs are injected into the knee joint,
most of them migrate into the synovium and surviving cells
maintained their MSC properties without differentiating into
another lineage. Then they produce PRG-4 and BMPs for cartilage
homeostasis and TSG-6 for anti-inﬂammation [Fig. 5(E)]. These
factors contribute to chondroprotection and prevent the progres-
sion of OA, but migrated MSCs do not survive in the long term, and
the number of MSCs rapidly decreases after the injection. Therefore
a single administration of synovial MSCs had only a temporary and
a minimal effect against the chronic pathology in OA. When sy-
novial MSCs are injected weekly, the number of MSCs and the
chondroprotective effect is maintained in the long term, which
conﬁrms reliable effects in inhibiting OA progression.
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